Drug Overview

Larotrectinib is a groundbreaking “Smart Drug” that represents a major shift in how we treat cancer. Traditionally, doctors chose medicines based on where the cancer started, such as the lungs or the breast. Larotrectinib is different because it is a Targeted Therapy that treats cancer based on a specific genetic change, regardless of where the tumor is located in the body.

This medication is often referred to as a “tumor-agnostic” therapy. It is specifically designed to seek out and block a very rare genetic abnormality. Because it is so precise, it can often work on many different types of cancer in both children and adults, offering hope even when other treatments have failed.

Generic Name: Larotrectinib
US Brand Names: Vitrakvi
Drug Class: Tropomyosin Receptor Kinase (TRK) Inhibitor
Route of Administration: Oral (Capsule or Oral Solution/Liquid)
FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

To understand how larotrectinib works, imagine a cell has a “light switch” that controls growth. In some cancers, a mistake in the DNA causes two genes to fuse together. This is called an NTRK gene fusion. This mistake creates an abnormal “TRK fusion protein” that keeps the growth switch stuck in the “ON” position, causing the cancer to grow uncontrollably.

At the molecular level, larotrectinib acts as a highly selective “key” that fits into the TRK protein:

Kinase Inhibition: Larotrectinib enters the cancer cell and binds directly to the ATP-binding site of the TRK receptors (specifically TRKA, TRKB, and TRKC).
Signal Interruption: By blocking this site, the drug prevents the protein from sending growth signals through pathways like MAPK, PI3K, and PLC-gamma.
Stopping the Cycle: Without these signals, the “switch” is turned off. The cancer cell stops dividing and eventually dies (a process called apoptosis).
Targeted Precision: Because larotrectinib is designed only for the abnormal TRK protein, it tends to cause fewer side effects than traditional chemotherapy, which attacks all fast-growing cells.

FDA-Approved Clinical Indications

Larotrectinib is approved for use in both adult and pediatric patients whose tumors have a specific genetic feature.

Oncological Uses

NTRK Gene Fusion-Positive Solid Tumors: For patients whose cancer has an NTRK gene fusion without a known resistance mutation.
Metastatic or Unresectable Cancer: For tumors that have spread to other parts of the body or cannot be removed with surgery.
Advanced Disease: For patients who have no satisfactory alternative treatments or whose cancer progressed after other treatments.

Non-Oncological Uses

There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Larotrectinib is taken by mouth, either as a capsule or a liquid. It is usually taken twice a day, with or without food.

Patient Group	Standard Dosage	Frequency	Administration Method
Adults	100 mg	Twice Daily	Oral (Capsule or Liquid)
Pediatrics ($BSA \ge 1.0 m^2$)	100 mg	Twice Daily	Oral (Capsule or Liquid)
Pediatrics ($BSA < 1.0 m^2$)	$100 mg/m^2$	Twice Daily	Oral (Liquid preferred)

Dose Adjustments:

Hepatic (Liver) Insufficiency: For patients with moderate to severe liver impairment, the starting dose is usually reduced by 50%.
Side Effect Management: If severe side effects occur, a doctor may temporarily stop the drug or reduce the dose (e.g., from 100 mg to 75 mg or 50 mg).

Clinical Efficacy and Research Results

Clinical data from 2020–2025 continue to show that larotrectinib is highly effective for patients with the NTRK mutation.

Overall Response Rate (ORR): Long-term data across multiple trials (NAVIGATE and SCOUT) shows an ORR of approximately 75% to 80%. This means the majority of patients saw their tumors shrink significantly.
Durability of Response: Many patients remain on the treatment for a long time. Research indicates that the median “Duration of Response” is over 32 months.
Pediatric Success: In children with infantile fibrosarcoma (a rare soft tissue cancer), the response rate has been reported as high as 90%, often allowing children to avoid disfiguring surgeries.
Survival Rates: Numerical data suggests that for those who respond, the 3-year overall survival rate is approximately 77%.

Safety Profile and Side Effects

Black Box Warning:

None. Larotrectinib does not currently have an FDA Black Box Warning.

Common Side Effects (>10%)

Fatigue: Feeling unusually tired or weak.
Nausea and Vomiting: General stomach upset.
Dizziness: Feeling lightheaded or unsteady.
Liver Enzyme Changes: Increase in AST and ALT levels (found via blood tests).
Constipation or Diarrhea: Changes in bowel habits.
Anemia: Low red blood cell counts.

Serious Adverse Events

Hepatotoxicity: Severe liver injury (monitored through frequent blood tests).
Neurological Problems: Confusion, difficulty speaking, or walking.
Bone Marrow Suppression: Significant drops in white blood cells or platelets.

Management Strategies

Liver Monitoring: Blood tests are usually performed every two weeks for the first month, then monthly.
Neurological Checks: Patients are encouraged to report any sudden “foggy” thinking or loss of balance immediately.

Research Areas

While larotrectinib is a standalone targeted therapy, current research is exploring Resistance Management. Some cancers eventually learn how to “bypass” the drug by creating new mutations. Scientists are developing “Next-Generation” TRK inhibitors to give to patients if larotrectinib stops working. Additionally, there is early research into combining larotrectinib with Immunotherapy to see if it can help the immune system recognize and attack TRK-fusion tumors even more effectively.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Next-Generation Sequencing (NGS): A mandatory genetic test to confirm the presence of an NTRK gene fusion.
Liver Function Tests (LFTs): To establish baseline liver health.
Complete Blood Count (CBC): To check baseline blood cell levels.

Precautions During Treatment

Grapefruit Interaction: Avoid grapefruit and grapefruit juice, as they can increase the drug’s levels in your blood to unsafe amounts.
St. John’s Wort: Avoid this herbal supplement, as it can make the drug less effective.
Birth Control: Larotrectinib can harm an unborn baby. Effective birth control is required during treatment and for one week after the last dose.

“Do’s and Don’ts” List

Do take the medicine at the same time every day to keep levels steady.
Do swallow capsules whole; do not crush or chew them.
Don’t skip doses. If you miss a dose by more than 6 hours, wait and take the next one at the regular time.
Don’t stop taking the medication without consulting your oncologist, even if you feel better.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Larotrectinib is a prescription medication that must be managed by an oncologist. Always consult with your healthcare professional regarding your specific diagnosis and treatment plan. Information reflects data available as of early 2026.